Biotech Values

[drbio45]

Poniard needed the small cell lung cancer trial to work.

If that would have worked the sales in that market would have paid for the trials in other indications, so the company or partner would have had much less risk in advancing into other indications because they would have been internally funded

Poniard picked up this drug from big pharma, I believe GSK. The data in colon cancer wasn't as good as I thought it would be in fact the pfs in the soc arm outperformed their drug. The side effects are less. It will cost a lot of money to run a survival trial in the indication and if the survival is equal but they show lower neuro side effects but higher blood based side effects how is a decision made to approve the drug.

I wrote the above and below info before seeing the Overall survival was lower on the Pico arm. The purpose of running this trial was supposed to support the notion that since there were fewer neurological side effects the patients could stay on the active arm longer and the survival would improve. That obviously didn't happen.

I think there prostate cancer data is a lot better than the colon cancer data but by then Cougar's drug, now J and J or Medivation's drug will probably be approved so they would have to have data against those two drugs or after patients have relapsed those drugs before it could be approved.

I am surprised that the stock isn't trading at 10 cents. If the trial had failed in 2008 instead of 2009, that is where it would have been trading.